Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

decitabine

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

DNMT inhibitor

Related drugs:

‹

azacitidine (75)

decitabine/cedazuridine (10)

azacitidine oral (7)

azacitidine (75)

decitabine/cedazuridine (10)

azacitidine oral (7)

›

No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1
No biomarker	Myelodysplastic Syndrome	No biomarker	Myelodysplastic Syndrome	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1	decitabine Sensitive: A1 - Approval decitabine Sensitive : A1
TP53 mutation	Myelodysplastic Syndrome	TP53 mutation	Myelodysplastic Syndrome	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2
TP53 mutation	Acute Myelogenous Leukemia	TP53 mutation	Acute Myelogenous Leukemia	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2	decitabine Sensitive: C2 – Inclusion Criteria decitabine Sensitive : C2
DNMT3A mutation	Myelodysplastic Syndrome	DNMT3A mutation	Myelodysplastic Syndrome	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3
U2AF1 mutation	Myelodysplastic Syndrome	U2AF1 mutation	Myelodysplastic Syndrome	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3	decitabine Resistant: C3 – Early Trials decitabine Resistant : C3
NPM1 mutation	Myelodysplastic Syndrome	NPM1 mutation	Myelodysplastic Syndrome	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3	decitabine Sensitive: C3 – Early Trials decitabine Sensitive : C3
KMT2A-PTD	Acute Myelogenous Leukemia	KMT2A-PTD	Acute Myelogenous Leukemia	cytarabine + decitabine + vorinostat Sensitive: C3 – Early Trials cytarabine + decitabine + vorinostat Sensitive : C3	cytarabine + decitabine + vorinostat Sensitive: C3 – Early Trials cytarabine + decitabine + vorinostat Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3	decitabine + clofarabine Sensitive: C3 – Early Trials decitabine + clofarabine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3